Although IDO inhibition is attractive as anti-cancer therapy because IDO promotes tolerance to tumors, the nonimmunological effects mediated by MT and other IDO modulators deserve consideration in bladder cancer. This evidence concerns the gene IDO1 and urinary bladder cancer.